E-scape Bio: Funding, Investors & Team (Sep 2026)
Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases. Escape Bio's pipeline includes candidates targeting known genetic drivers of multiple diseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4. E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States.
E-scape Bio has raised $73.0M across 1 funding round on record, the most recent an undisclosed round of $73.0M announced in Sep 2020.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
E-scape Bio Company Profile and Key Stats
Latest funding round on record: Sep 2020.
E-scape Bio Funding Rounds
E-scape Bio Founders and Leadership Team
No contact details are on record for this team yet.
E-scape Bio Funding Compared to Other Biotechnology Startups
E-scape Bio's latest round of $73.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like E-scape Bio in Biotechnology and South San Francisco
Companies Similar to E-scape Bio
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
E-scape Bio Funding FAQs
What does E-scape Bio do?
Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases. Escape Bio's pipeline includes candidates targeting known genetic drivers of multiple diseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4. E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States.
How much funding has E-scape Bio raised?
E-scape Bio has raised $73.0M across 1 round on record. The most recent is an undisclosed round of $73.0M announced in Sep 2020.
When did E-scape Bio last raise funding?
E-scape Bio's most recent funding round on record is an undisclosed round of $73.0M, announced in Sep 2020.
Who is the CEO of E-scape Bio?
Julie Smith is listed as CEO at E-scape Bio.
Where is E-scape Bio headquartered?
E-scape Bio is based in South San Francisco, California, United States.
How many employees does E-scape Bio have?
E-scape Bio is in the 11-50 employee band.
How does E-scape Bio's funding compare to other Biotechnology startups?
E-scape Bio's latest round of $73.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's E-scape Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for E-scape Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.